| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $3,335,382 | 22 | 100 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 0 | $0 | 4 | $44,636 | $-44,636 |
| Sanders Corazon (Corsee) D. | director | 0 | $0 | 1 | $89,923 | $-89,923 |
| Crombez Eric | EVP and Chief Medical Officer | 0 | $0 | 3 | $189,163 | $-189,163 |
| Pinion John Richard | See Remarks | 0 | $0 | 1 | $228,661 | $-228,661 |
| Harris Erik | EVP & Chief Commercial Officer | 0 | $0 | 1 | $240,289 | $-240,289 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 0 | $0 | 4 | $470,156 | $-470,156 |
| Horn Howard | Chief Financial Officer | 0 | $0 | 7 | $832,143 | $-832,143 |
| KAKKIS EMIL D | President & CEO | 0 | $0 | 1 | $1.24M | $-1.24M |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Over the last 12 months, insiders at Ultragenyx Pharmaceutical Inc. have bought $0 and sold $3.34M worth of Ultragenyx Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at Ultragenyx Pharmaceutical Inc. have bought $0 and sold $6.57M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $218,150 was made by KAKKIS EMIL D (President & CEO) on 2019‑09‑11.
| 2026-04-01 | Sale | Horn Howard | Chief Financial Officer | 4,683 0.0047% | $20.97 | $98,203 | +9.21% | |
| 2026-03-10 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 3,508 0.0036% | $22.67 | $79,526 | -5.43% | |
| 2026-03-06 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 6,018 0.0063% | $21.40 | $128,785 | +2.16% | |
| 2026-03-03 | Sale | Horn Howard | Chief Financial Officer | 1,635 0.0016% | $22.40 | $36,624 | -1.88% | |
| 2026-03-02 | Sale | KAKKIS EMIL D | President & CEO | 54,404 0.0549% | $22.80 | $1.24M | -5.69% | |
| 2026-03-02 | Sale | Pinion John Richard | See Remarks | 10,029 0.0101% | $22.80 | $228,661 | -5.69% | |
| 2026-03-02 | Sale | Harris Erik | EVP & Chief Commercial Officer | 10,539 0.0106% | $22.80 | $240,289 | -5.69% | |
| 2026-03-02 | Sale | Horn Howard | Chief Financial Officer | 8,409 0.0084% | $22.70 | $190,914 | -5.69% | |
| 2026-03-02 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 8,135 0.0082% | $22.80 | $185,478 | -5.69% | |
| 2026-03-02 | Sale | Crombez Eric | EVP and Chief Medical Officer | 7,029 0.0071% | $22.80 | $160,261 | -5.69% | |
| 2026-03-02 | Sale | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 1,632 0.0016% | $22.80 | $37,210 | -5.69% | |
| 2026-02-02 | Sale | Horn Howard | Chief Financial Officer | 3,061 0.003% | $23.56 | $72,117 | -9.77% | |
| 2026-01-02 | Sale | Horn Howard | Chief Financial Officer | 3,150 0.0032% | $22.84 | $71,946 | -3.60% | |
| 2025-12-29 | Sale | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 85 <0.0001% | $34.38 | $2,922 | +15.52% | |
| 2025-12-10 | Sale | Horn Howard | Chief Financial Officer | 3,081 0.0032% | $36.38 | $112,087 | -36.06% | |
| 2025-10-13 | Sale | Horn Howard | Chief Financial Officer | 7,942 0.0081% | $31.51 | $250,252 | -24.30% | |
| 2025-09-18 | Sale | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 64 <0.0001% | $29.17 | $1,867 | -14.94% | |
| 2025-09-12 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 2,450 0.0026% | $31.17 | $76,367 | -16.61% | |
| 2025-09-05 | Sale | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 84 <0.0001% | $31.39 | $2,637 | -11.17% | |
| 2025-06-20 | Sale | Sanders Corazon (Corsee) D. | director | 2,405 0.0026% | $37.39 | $89,923 | -21.89% |
| KAKKIS EMIL D | President & CEO | 658994 0.682% | $16.59M | 2 | 28 | +13.31% |
| Pinion John Richard | See Remarks | 110026 0.1139% | $2.77M | 0 | 12 | |
| Harris Erik | EVP & Chief Commercial Officer | 89515 0.0926% | $2.25M | 0 | 19 | |
| Horn Howard | Chief Financial Officer | 80351 0.0832% | $2.02M | 0 | 9 | |
| Crombez Eric | EVP and Chief Medical Officer | 76301 0.079% | $1.92M | 0 | 7 | |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 66820 0.0692% | $1.68M | 0 | 32 | |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 48670 0.0504% | $1.23M | 0 | 33 | |
| Sanders Corazon (Corsee) D. | director | 15344 0.0159% | $386,361.92 | 0 | 5 | |
| FMR LLC | 10 percent owner | 3260240 3.3739% | $82.09M | 1 | 0 | +10.41% |
| TPG Group Holdings (SBS) Advisors, Inc. | 2596420 2.687% | $65.38M | 0 | 1 | ||
| Kassberg Thomas Richard | CBO & EVP | 265238 0.2745% | $6.68M | 1 | 26 | +10.12% |
| Sharp Shalini | EVP, Finance | 97812 0.1012% | $2.46M | 1 | 28 | +10.12% |
| Huang Dennis Karl | See Remarks | 75314 0.0779% | $1.9M | 0 | 7 | |
| Dier Mardi | CFO & Executive Vice President | 66695 0.069% | $1.68M | 0 | 5 | |
| Aliski William | director | 65704 0.068% | $1.65M | 1 | 13 | +10.12% |
| Bedrosian Camille L | EVP and Chief Medical Officer | 46720 0.0483% | $1.18M | 0 | 12 | |
| Fust Matthew K | director | 14860 0.0154% | $374,174.80 | 1 | 6 | +10.12% |
| AGARWAL SUNIL | Chief Medical Officer | 9528 0.0099% | $239,915.04 | 0 | 12 | |
| SIEGALL CLAY B | director | 2550 0.0026% | $64,209.00 | 0 | 2 |
$52,263,649 | 70 | 1.18% | $2.54B | |
$47,419,530 | 58 | 17.20% | $2.28B | |
$586,486,795 | 47 | 4.28% | $2.39B | |
$613,304,943 | 46 | 11.85% | $2.22B | |
$1,603,489 | 30 | 98.90% | $2.25B | |
$62,927,079 | 29 | 14.02% | $2.72B | |
$18,854,717 | 21 | 22.51% | $2.13B | |
$103,194,328 | 13 | 9.02% | $2.22B | |
$18,336,420 | 12 | 24.03% | $2.94B | |
$94,976,497 | 10 | -10.72% | $2.1B | |
$1,248,715 | 10 | 5.66% | $2.7B | |
$2,859,892 | 10 | 29.21% | $2.15B | |
$45,445,266 | 9 | -24.96% | $2.83B | |
Ultragenyx Pharmaceutical Inc. (RARE) | $4,623,072 | 7 | 11.07% | $2.43B |
$1,407,368 | 5 | 31.21% | $2.45B | |
$3,200,000 | 5 | -11.36% | $2.77B | |
$666,380 | 5 | -16.60% | $2.57B | |
$24,000,085 | 4 | 33.26% | $2.68B | |
$5,000,000 | 1 | -22.84% | $2.24B |
| Increased Positions | 171 | +49.14% | 18M | +18.8% |
| Decreased Positions | 160 | -45.98% | 19M | -20.22% |
| New Positions | 56 | New | 5M | New |
| Sold Out Positions | 66 | Sold Out | 7M | Sold Out |
| Total Postitions | 359 | +3.16% | 95M | -1.41% |
| Vanguard Group Inc | $239,132.00 | 10.56% | 10.13M | -80,694 | -0.79% | 2025-09-30 |
| Fmr Llc | $171,886.00 | 7.59% | 7.28M | +5M | +179.63% | 2025-09-30 |
| Blackrock, Inc. | $151,636.00 | 6.69% | 6.43M | +169,118 | +2.7% | 2025-09-30 |
| Jpmorgan Chase & Co | $94,670.00 | 4.18% | 4.01M | +750,561 | +23.02% | 2025-09-30 |
| Sands Capital Management, Llc | $88,969.00 | 3.93% | 3.77M | -173,632 | -4.4% | 2025-09-30 |
| State Street Corp | $87,143.00 | 3.85% | 3.69M | +1M | +43.55% | 2025-09-30 |
| Rtw Investments, Lp | $76,895.00 | 3.39% | 3.26M | +2M | +90.83% | 2025-09-30 |
| Baker Bros. Advisors Lp | $65,436.00 | 2.89% | 2.77M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $54,520.00 | 2.41% | 2.31M | -576,094 | -19.96% | 2025-09-30 |
| Jacobs Levy Equity Management, Inc | $51,158.00 | 2.26% | 2.17M | +2M | +614.09% | 2025-09-30 |